---
title: "Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F"
url: "https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-02-25"
section: "Listings"
tickers: "NASDAQ:UPC"
source: "https://www.sec.gov/Archives/edgar/data/1809616/000121390025017079/ea023172101ex99-1_universe.htm"
summary: "The company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on"
---

By the aibio.space news desk.

Sources

- [Universe Pharmaceuticals Inc 6-K (2025-02-25)](https://www.sec.gov/Archives/edgar/data/1809616/000121390025017079/ea023172101ex99-1_universe.htm)

[UPC](https://aibio.space/companies/universe-pharmaceuticals/)

2025-02-25

# Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F

Tickers [UPC](https://aibio.space/companies/universe-pharmaceuticals/)

The company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.

## Key facts

- **Company**: Universe Pharmaceuticals Inc (NASDAQ: UPC)

- **News type**: Listings

- **Primary source**: [Universe Pharmaceuticals Inc 6-K (2025-02-25)](https://www.sec.gov/Archives/edgar/data/1809616/000121390025017079/ea023172101ex99-1_universe.htm)

*A stone federal courthouse. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Universe Pharmaceuticals Inc (Nasdaq: [UPC](https://aibio.space/companies/universe-pharmaceuticals/)) said on February 25, 2025 that it received a staff determination notice from the Nasdaq Listing Qualifications Department on February 19, 2025. The notice says the company is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024. Nasdaq said this matter serves as an additional basis for delisting the company's securities.

The failure to file the Form 20-F on time is a violation of Nasdaq Listing Rule 5250(c)(1), according to the notice.

The company is already before a Hearings Panel for failing to comply with Listing Rule 5550(a)(2). It was therefore given until February 26, 2025 to request a stay of the suspension of its securities while the Panel decides. The company said it intends to request a stay before that date.

Universe Pharmaceuticals said it is working on completing and filing the delayed Form 20-F. The company made the announcement under Nasdaq Listing Rule 5810(b), which requires prompt disclosure of a deficiency notification.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

UPC

Universe Pharmaceuticals Inc

NASDAQ · China

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F", 2025-02-25, https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/